Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia - A case report

#4247

Introduction: Idiopathic Diffuse Neuroendocrine Diffuse Neuroendocrine Hyperplasia is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women, Of available therapies, somatostatin analogs and mTOR are the most promising

Aim(s): A 51-year-old hypertensive woman with no other history, with 15 years of symptoms characterized by dyspnea of great effort and exercise intolerance, classified as asthma, treated with short-acting beta 2 agonist, in the last 5 years increased dyspnea, received therapy with inhaled corticosteroid without improvement, chest CT with finding of multiple bilateral pulmonary nodules between 2 and 8 mm classified as low risk for malignancy, no symptomatic control despite adjustment in therapy with ICS and SABA, during the last year deterioration of dyspnea and quality of life, spirometry with obstructive pattern with FEV1/FVC of 69% and FEV1 of 1. 21 L. A lower lobe biopsy was performed with report of carcinoid tumorlets and idiopathic diffuse neuroendocrine hyperplasia, Ga68 DOTANOC PET was performed with the finding of pulmonary nodules up to 6 mm of soft tissue density, no radiotracer uptake. Dyspnea was classified with mMRC 3 and deterioration in the QL, therapy was indicated with Lanreotide at a dose of 120 mg SC every 30 days.

Materials and methods: Case report

Conference:

Presenting Author: Florez A

Authors: Florez A, Unigarro M, Fernandez J, Viola L, Perez G,

Keywords: neuroendocrine tumor, lung, idiopathic diffuse neuroendocrine hyperplasia, tumorlets,